Alphabet's Subsidiary Raises $2.1B to Accelerate Clinical Trials of AI-Developed Drugs

Isomorphic Labs, an AI-driven drug discovery company led by Demis Hassabis (co-founder of Alphabet), recently announced a $2.1 billion Series B funding round. The round was led by Thrive Capital, with participation from Alphabet and several sovereign wealth funds, with the goal of advancing AI-discovered drug candidates into clinical trials.
Founded in 2021 and headquartered in London, the company is dedicated to redefining drug discovery through artificial intelligence. This investment not only sets a new record in the field but also reflects strong market confidence in AI's ability to tackle major human health challenges.
Advancing the IsoDDE Smart Platform
The funding will be used to expand the company's internal AI development platform, IsoDDE, and to grow its global talent team. The platform integrates multiple proprietary AI models that operate across various therapeutic areas and drug classes, significantly shortening the early stages of drug development.
Hassabis noted that the company's core R&D approach has been validated, and the current priority is to scale the technology. By combining reliable research data with efficient AI algorithms, the ambitious mission of "solving all diseases" is gradually moving from vision to reality.
Strengthening Partnerships with Pharmaceutical Giants
Isomorphic Labs has formed deep partnerships with leading global pharmaceutical companies, including Novartis, Eli Lilly, and Johnson & Johnson. Through shared technology platforms and R&D pipelines, these industry leaders are using AI to overcome the traditional drug development bottleneck of high costs and low yields.
Industry experts view this funding as a pivotal moment for AI-driven drug discovery as it enters clinical validation. As more AI-developed drugs move into clinical trials, the healthcare sector is poised for a computing-powered efficiency revolution, offering renewed hope for patients worldwide.
Related article
U.S. Stocks Hit Historic Milestone as AI and Aerospace Giants Prepare for Trillion-Dollar Debut
Elon Musk, Sam Altman, and Dario Amodei, three titans of the technology sector, are advancing toward initial public offerings for their respective ventures. With SpaceX, OpenAI, and Anthropic—three industry behemoths nearing trillion-dollar valuation
Swedish AI Startup Lovable Eyes $13.2 Billion Valuation After Major Funding Round
As AI-driven coding tools gain traction, Swedish startup Lovable has secured a major funding round. The company aims to raise $3 billion, potentially boosting its valuation to $13.2 billion—double the $6.6 billion recorded last December. Menlo Ventur
Google Tests Remy AI Agent for Gemini as Focus Shifts to User Control
According to Business Insider, Google is testing Remy, a new AI personal agent for Gemini. This tool aims to execute tasks on behalf of users, streamlining both professional workflows and daily routines.Currently, Remy is undergoing testing in an int
Related Special Topic Recommendations
Comments (1)
0/500

Isomorphic Labs, an AI-driven drug discovery company led by Demis Hassabis (co-founder of Alphabet), recently announced a $2.1 billion Series B funding round. The round was led by Thrive Capital, with participation from Alphabet and several sovereign wealth funds, with the goal of advancing AI-discovered drug candidates into clinical trials.
Founded in 2021 and headquartered in London, the company is dedicated to redefining drug discovery through artificial intelligence. This investment not only sets a new record in the field but also reflects strong market confidence in AI's ability to tackle major human health challenges.
Advancing the IsoDDE Smart Platform
The funding will be used to expand the company's internal AI development platform, IsoDDE, and to grow its global talent team. The platform integrates multiple proprietary AI models that operate across various therapeutic areas and drug classes, significantly shortening the early stages of drug development.
Hassabis noted that the company's core R&D approach has been validated, and the current priority is to scale the technology. By combining reliable research data with efficient AI algorithms, the ambitious mission of "solving all diseases" is gradually moving from vision to reality.
Strengthening Partnerships with Pharmaceutical Giants
Isomorphic Labs has formed deep partnerships with leading global pharmaceutical companies, including Novartis, Eli Lilly, and Johnson & Johnson. Through shared technology platforms and R&D pipelines, these industry leaders are using AI to overcome the traditional drug development bottleneck of high costs and low yields.
Industry experts view this funding as a pivotal moment for AI-driven drug discovery as it enters clinical validation. As more AI-developed drugs move into clinical trials, the healthcare sector is poised for a computing-powered efficiency revolution, offering renewed hope for patients worldwide.
U.S. Stocks Hit Historic Milestone as AI and Aerospace Giants Prepare for Trillion-Dollar Debut
Elon Musk, Sam Altman, and Dario Amodei, three titans of the technology sector, are advancing toward initial public offerings for their respective ventures. With SpaceX, OpenAI, and Anthropic—three industry behemoths nearing trillion-dollar valuation
Swedish AI Startup Lovable Eyes $13.2 Billion Valuation After Major Funding Round
As AI-driven coding tools gain traction, Swedish startup Lovable has secured a major funding round. The company aims to raise $3 billion, potentially boosting its valuation to $13.2 billion—double the $6.6 billion recorded last December. Menlo Ventur





Home






